MedTrace Logo

Neoadjuvant Immunotherapy in Advanced NSCLC

NCT05137912 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2022-02-07

No results posted yet for this study

Summary

A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC. One such example would be to evaluate either single agent or an immunotherapy combination with chemotherapy. Following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.

Conditions

  • Lung Cancer, Non-small Cell

Interventions

BIOLOGICAL

Immunotherapy

Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA. Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy.

Sponsors & Collaborators

  • Power Life Sciences Inc.

    lead INDUSTRY

Principal Investigators

  • Michael B Gill · [Power Life Sciences Inc.](www.withpower.com)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-09-01
Completion
2022-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137912 on ClinicalTrials.gov